Meera J. Desai - 25 May 2023 Form 4 Insider Report for Adamis Pharmaceuticals Corp

Role
Director
Signature
/s/ David C. Benedicto, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
25 May 2023
Net transactions value
$0
Form type
4
Filing time
30 May 2023, 18:15:16 UTC
Previous filing
06 Oct 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADMP Common Stock Award +3,138 3,138 25 May 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 22, 2023, Adamis Pharmaceuticals Corporation ("Adamis") effected a 1 for 70 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F2 Received in exchange for common stock of DMK Pharmaceuticals Corporation, a privately held corporation ("DMK"), in connection with the merger of DMK into a subsidiary of Adamis (the "Merger"). On the effective date of the Merger, the closing price of Adamis common stock was $2.50 per share.